Please login to the form below

Not currently logged in

Janssen buys hepatitis C candidate from GSK

J&J subsidiary acquires rights to NS5A inhibitor

Janssen logo 

Johnson & Johnson's Janssen unit has bolstered its hepatitis C virus treatment portfolio with the acquisition of a phase II candidate from GlaxoSmithKline (GSK).

Janssen has taken full ownership of GSK2336805, a once-daily NS5A inhibitor that GSK had advanced into phase II testing for chronic hepatitis C infection in adults with compensated liver disease, including all stages of liver fibrosis.

The company plans to start trials combining GSK2336805 with its non-nucleoside polymerase inhibitor TMC647055 and simeprevir (TMC435) - an NS3/4A protease inhibitor developed with Sweden's Medivir.

"This addition will broaden our clinical development programme as we continue to look for new investigational interferon-free treatment combinations to combat the hepatitis C virus," said Janssen's hepatitis project head Gaston Picchio.

J&J is in a race with a number of other companies to bring an all-oral treatment regimen for hepatitis C to market in order to free patients from the need for injectable and sometimes hard-to-tolerate interferon alfa-based treatment.

Simeprevir has been submitted for regulatory approval in the US, Canada and Europe, and was approved last month in Japan, but a number of other companies are already in the latter phases of development for all-oral hepatitis C regimens.

AbbVie and Gilead Sciences are currently thought to be leading the charge on interferon-free regimens with combination therapies in phase III, although Bristol-Myers Squibb, Boehringer Ingelheim and Merck & Co have also reach the latter stages of testing with their own candidates.

The sheer scale of the hepatitis C virus market in terms of the number of people infected worldwide means it is expected to swell to more than $20bn a year once all-oral regimens hit the market.

Article by
Phil Taylor

9th October 2013

From: Research, Sales



Featured jobs

Subscribe to our email news alerts


Add my company Conferences, Events and Exhibition Stands is one of the UK’s leading event and exhibition agencies, specialising in healthcare. We understand your communication goals, whether...

Latest intelligence

The Challenges Of UX In Healthcare: Technology To Change Lives
Blue Latitude Health Director and Head of Customer Experience Elisa Del Galdo explores the latest digital healthcare trends and reveals the innovations changing the sector today....
It’s all about patient outcomes… right?
Lessons from history: a design thinking perspective...
Emma Walmsley 2
30 Women Leaders in UK Healthcare (part 3)
Continuing our special feature on Women Leaders in UK Healthcare...